HRS-7535: when an oral weight-loss drug is packed into a “US shell”, what exactly did Hengrui sell?

The first thing to clear up is not to confuse HRS-7535 with Hengrui’s other frequently mentioned “oral ribupatide”. They are two different molecules:

HRS-7535 (overseas code KAI-7535) is an oral small-molecule GLP-1 receptor mono-agonist — non-peptide, once daily; mechanistically it activates the GLP-1 receptor to promote insulin secretion, suppress glucagon and slow gastric emptying, and centrally enhances satiety and suppresses appetite.

HRS-9531 (i.e. ribupatide, KAI-9531) is a GLP-1/GIP dual-agonist peptide, available as both a weekly subcutaneous injection and an oral tablet, with Phase 3 weight loss of 17.7%; its China marketing application has already been filed. It is the true face of Hengrui’s weight-loss portfolio.

This relationship is key: within Hengrui’s metabolic map, HRS-7535 is an “important but not flagship” asset. Its visibility comes from its position as “China’s first oral small-molecule GLP-1 to enter Phase 3”, not from efficacy leadership — which belongs to HRS-9531. The portfolio also includes a preclinical GLP-1/GIP/GCG triple agonist (HRS-4729), a once-weekly insulin, and the marketed retagliptin family of glucose-lowering products. In other words, Hengrui has covered the incretin line from oral to injectable and from single- to triple-agonist; HRS-7535 is just one piece of the puzzle.

Why Hengrui went down this road has to be seen in the context of the 2023–2024 wave of “NewCo going global”. At the time, a batch of Chinese biopharma assets went global en masse by “setting up a new US company, with the Chinese party licensing and holding equity, and top funds injecting capital”; Hengrui’s GLP-1 deal was one of the most iconic cases. For a large Chinese pharma whose innovative drugs had only just passed half of sales and which was trying to transform from “China leader” into “global player”, GLP-1 was a strategic category it had to win; but the global obesity market is monopolized by the twin peaks of Novo Nordisk and Lilly, and going it alone was neither realistic nor economical. Packing the asset into a specialized global vehicle while stepping back to be a shareholder and China operator was the pragmatic solution balancing “going global” with “risk control”. Understanding this motive explains why China’s most advanced oral GLP-1 was handed over so early and so completely.

HRS-7535’s China Phase 2 weight-loss data are not bad. It was a 235-patient, 36-week randomized double-blind placebo-controlled study in which non-diabetic adults with obesity/overweight (BMI 28–40) were randomized to 30/60/120/180 mg once daily or placebo. The result showed clear dose dependence: at Week 26, the 180 mg arm lost 6.87% body weight placebo-adjusted (P<0.0001); at Week 36, the 180 mg arm lost 9.50% from baseline (placebo just 1.40%), with 35.4% of subjects losing 10% or more. Safety was dominated by mild-to-moderate gastrointestinal reactions (nausea, diarrhea, vomiting, most frequent during titration), with 2.1% discontinuing due to adverse events.

The problem is not the data themselves but the coordinate system they sit in. Put it alongside global peers and the awkwardness is immediately apparent:

Cross-trial comparison shows only direction and cannot be treated as head-to-head, but the direction is clear enough: against its most direct global rival orforglipron, HRS-7535 is two years behind and weaker in efficacy; within its own portfolio, it is overshadowed by the dual-agonist HRS-9531. The only stories it can really tell are the convenience and cost of the “oral small-molecule” dosage form itself, and the domestic time window of “fastest progress in China”.

An often overlooked rival is oral semaglutide. Novo Nordisk’s oral formulation has already educated the market on “oral GLP-1”, though it is a peptide requiring fasting and restricted water intake. As a small molecule, HRS-7535 could in theory go a step further on dosing convenience — provided its own food-effect data are friendly enough. As for gastrointestinal reactions, nausea, vomiting and diarrhea are common across the GLP-1 class, HRS-7535 being no exception, and are more frequent during dose titration. This is both a challenge for real-world adherence and a sign that, after launch, mature titration schemes and patient education will be needed to keep discontinuation down. Looked at another way, none of these are weaknesses unique to it; what really differentiates it from peers is still the combination of the “oral small-molecule” dosage form and cost.

This is the most solid part of HRS-7535. Its China registration follows the standard path of independent Phase 3 trials and self-filing, with no bridging and no ambiguity from cross-regional dependence. The glucose-lowering Phase 3 uses an active-comparator head-to-head design against dapagliflozin, with change in HbA1c at 32 weeks as the primary endpoint; the weight-loss Phase 3 is running in parallel, and both studies are expected to read out during 2026. Choosing an active comparator rather than placebo alone prepares for both registration and NRDL negotiation — if it can show superiority over dapagliflozin, that becomes a hard weapon for hospital listing and payer negotiation.

What needs a bucket of cold water is “acceleration”. There is no public sign of HRS-7535 receiving Breakthrough Therapy Designation or priority review. In a lane already packed with semaglutide, tirzepatide and mazdutide, the bar for “addressing unmet clinical need” is already high. So when planning the timeline, the baseline should be the standard Phase 3-to-marketing-application pace, treating acceleration as a possible upside surprise rather than a dependency.

The head-to-head against dapagliflozin design itself is worth a second look. In diabetes, SGLT2 inhibitors (dapagliflozin being the archetype) are one of the mainstays of oral glucose-lowering therapy; putting HRS-7535 directly opposite it declares that Hengrui is fighting not just for “another GLP-1”, but for “the better one among oral glucose-lowering drugs”. If the 32-week HbA1c result shows superiority, this card carries real weight for hospital listing and at the NRDL negotiating table; if it is merely non-inferior, the differentiation narrative collapses noticeably. That is why the 2026 readout is almost a “make-or-break” battle for HRS-7535.

Fast registration is an advantage, but the commercial window is narrowing. Tirzepatide entered China in 2025; semaglutide and tirzepatide cut prices sharply in 2026, bringing competition forward; mazdutide was approved for weight management in June 2025 and for diabetes in September. By the time HRS-7535 launches around 2027–2028, how much of a head start remains for “the first oral small molecule” will depend largely on how fast orforglipron registers in China.

This is the part of the molecule most worth telling. On May 16, 2024, Hengrui licensed the worldwide rights outside Greater China to three GLP-1 assets — HRS-7535, HRS-9531 and HRS-4729 — as a whole to a purpose-built US company, Hercules CM NewCo (renamed Kailera Therapeutics in October of that year), keeping Greater China for itself. The elegance of this structure is that it is not a traditional “outright sale”, but a design of “trading equity for global execution”.

Translated into business language: with a modest upfront (US$100 million, for a portfolio containing a dual-agonist peptide in Phase 3, an oral small molecule and a preclinical triple agonist), Hengrui obtained three things — outsourcing the huge cash burn of global Phase 3 and commercialization to a well-funded licensee (which has raised US$1 billion in total); sharing in the company’s future appreciation (including a potential Nasdaq listing) through a nearly 20% stake; and retaining all self-commercialization rights in China as a value anchor.

HRS-7535 does not lead globally and Hengrui has no overseas commercial platform; building its own team to push global Phase 3 would take too long and cost too much. Packing it into a US shell backed by top life sciences funds both transfers overseas execution risk and keeps the upside in equity and sales milestones. Note that, unlike the textbook approach of “licensing US/Europe/Japan separately to multiple partners”, here “all remaining global markets go in one go to a single new company”, with regional fragmentation deferred to the company’s possible future sublicensing.

This “equity for global” design also hides a thread that is highly sensitive to capital markets. The bulk of the value Hengrui gets from this deal is not in the US$100 million upfront, but in the future appreciation of its nearly 20% stake and the realization of up to US$5.725 billion in sales milestones — both highly dependent on whether the licensee can take the products all the way to market and win recognition in the primary and secondary markets. The company has completed a US$400 million Series A and US$600 million Series B and is preparing to list on Nasdaq, so its funding is not tight; but valuation sentiment in the GLP-1 space, and whether it can truly build commercial capability in the gap between Novo and Lilly, are variables in the book value of Hengrui’s stake. Put simply, Hengrui has exchanged part of its “molecule risk” for “capital market risk”.

Another hidden thread is geopolitics. Policy friction between China and the US in biopharma (such as legislative moves targeting Chinese biotechnology) could affect the stability and overseas pace of such “Chinese asset + US shell” structures. This is not unique to HRS-7535 but a systemic risk shared by every NewCo model. For Hengrui, the rational approach is to manage the value of this stake as a range across multiple scenarios, rather than booking it on a single optimistic path.

In a lane that is fighting a price war, cost structure often matters more to survival than a few tenths of a percentage point of efficacy. This is precisely the underrated side of HRS-7535.

It is an oral small-molecule tablet; the cost of chemically synthesized API and formulation scale-up is far lower than for peptide injectables, let alone oral peptides that need absorption enhancers. This means two things: first, manufacturing is not a rate-limiting step for development, and Hengrui’s mature small-molecule capacity can prepare commercial batches in parallel with Phase 3; second, in the 2026 pricing environment where semaglutide and tirzepatide have plunged together, low cost gives HRS-7535 room to “trade price for volume while protecting gross margin” — a structural advantage injectables and oral peptides find hard to copy.

The dosage form itself is also a selling point. An oral tablet completely avoids the pens, needles, cold chain and injection adherence burden of injectable GLP-1s, making it a natural fit for out-of-hospital, dual-channel, internet hospital and chronic disease management settings. On lifecycle, small molecules also lend themselves to fixed-dose combinations — Hengrui already has a successful precedent with retagliptin/metformin, and a future path to oral combinations with metformin or SGLT2 inhibitors is realistic.

Quantifying the cost advantage makes it more tangible. Peptide GLP-1 manufacturing requires complex solid- or liquid-phase synthesis, and injectables also need pens, needles and a cold chain; small molecules use standard chemical synthesis, with unit costs potentially an order of magnitude lower. When semaglutide and tirzepatide halved their prices in 2026 and moved competition forward to before launch, whoever has the lower cost curve can better withstand price cuts and more confidently trade low prices for share. HRS-7535 happens to sit at the most favorable end of the cost curve — in a crowded diabetes/obesity market, this may be more useful than a few extra tenths of a percentage point of efficacy.

The only thing left unclear is who is responsible for commercial manufacturing outside Greater China: whether the licensee builds its own or uses a CDMO, or Hengrui manufactures for export. This affects how the quality system extends across regions and how release interfaces are divided, and is an open variable that needs to be locked down in collaboration governance. Note also that orforglipron claims “no food or water restrictions”, while HRS-7535’s Phase 1 included a dedicated food-effect study — if it requires specific dosing conditions, its convenience narrative relative to orforglipron would be discounted, and this must be handled carefully on the label.

Bringing the view back inside Hengrui, the most delicate competition HRS-7535 faces comes from HRS-9531 under the same roof. The two overlap heavily in the “oral weight loss” setting: HRS-9531 has both an injectable and an oral tablet, and its dual-agonist efficacy (17.7%) is significantly higher than HRS-7535’s single-agonist efficacy (9.5%). When two oral GLP-1s compete for the same trial sites, the same weight-loss subjects, the same weight-loss budget and the same medical affairs resources, internal cannibalization is almost unavoidable.

This determines HRS-7535’s more realistic position in the portfolio: not to fight HRS-9531 for the high ground of “deep weight loss”, but to take an offset position — leading with the convenience and cost of oral glucose-lowering, targeting people who prefer oral therapy or are averse to injections, and going deep into out-of-hospital chronic disease management. Its portfolio value lies in filling the gaps of the “oral small-molecule” technology form and the “glucose-lowering” setting, not in creating another weight-loss product.

The urgency of this internal offset is further amplified by crowding in the external market. China’s weight-loss GLP-1 market is already a red ocean: beinaglutide, semaglutide and tirzepatide have launched in succession, mazdutide has been approved as the world’s first GCG/GLP-1 dual-agonist for weight loss, and more than a dozen others are in Phase 3. Add the collective price cuts of 2026, and the pure weight-loss space left for an “oral mono-agonist with moderate efficacy” is actually very narrow. This in turn confirms the earlier judgment: HRS-7535’s path to survival in China lies not on the frontal battlefield of weight loss, but on the flanks of glucose-lowering, cost and out-of-hospital channels.

Fortunately, while its “opportunity cost” is high, its “cost of failure” is low. Hengrui’s metabolic portfolio is deep enough that even if one asset fails it can be absorbed; small-molecule sunk costs are low, and if it really falls short, the better solution is to “downgrade” — narrowing to glucose-lowering or niche settings and redirecting weight-loss resources to HRS-9531 — rather than terminating it outright. What Hengrui needs to do is set clear criteria and accountable owners in advance for “when to go full speed and when to give way”, at the natural decision point of the two Phase 3 readouts in 2026.

HRS-7535 is a clear-eyed case: a molecule destined never to be a global leader can still be managed into a respectable business. Hengrui did not force itself to prop up a global commercialization effort it is not good at; instead, with the combination punch of “self-commercialize in China + package globally in exchange for equity”, it converted limited odds into certain cash flow and a sizable upside option. Its value anchor has quietly shifted from “how strong the molecule itself is” to “how deep the Chinese market can be mined + how high that US company can rise”.

This is precisely the most pragmatic side of globalization for large Chinese pharma — not every molecule needs to be best-in-class; acknowledging your position, designing a fallback, and putting other people’s money and platforms to work for you is itself a capability. Whether HRS-7535 delivers will ultimately depend on three things: whether liver safety holds in Phase 3, whether differentiated positioning in China can avoid the price war, and whether the US company called Kailera can truly monetize the global rights Hengrui handed it. In 2026, the answers will start to come in.